14 January 2022

Axxam announces the merger of its two German subsidiaries into Axxam GmbH

Axxam announced the merger of its two subsidiaries located in Germany. The decision is in line with the strategy to strengthen presence and investments in Germany and to offer to the several clients and partners integrating capacity and capabilities in early discovery research.
22 December 2021

Genenta Science listed on Wall Street Nasdaq

An excellence of the Italian Biotech reaches an extraordinary milestone: Genenta Science is the first national company to be listed on Wall Street in the American tech list.
03 November 2021

ReiThera Awarded Grant to Develop Next Generation Vaccines

Program funded by the Bill & Melinda Gates Foundation will use ReiThera’s GRAd platform technology to develop next generation vaccines against SARS-CoV-2 emerging variants and HIV
21 September 2021

3rd edition of the HealthTech Innovation Days - 4 & 5 October in Paris

Several speakers will share their views during the scheduled round-tables
07 September 2021

Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)

Tranche 4 consists of EUR 7.5 million and will primarily be used to support the Company’s development programs in diseases of the central nervous system.
18 July 2021

Axxam announces the launch of Muna Therapeutics ApS with EUR 60 Million to advance novel small molecule therapeutics for neurodegenerative diseases

Axxam is proud to announce that Muna Therapeutics, a biotech company founded in 2020 by Aarhus University, financed by Novo Seeds and receiving assets in exchange of equity from Axxam, was successful closing a EUR 60 million (US$ 73 million) Series A financing round

Partner

Where to find us

20149 Milan
Via Giovanni da Procida, 11
Show map 
Tel. +39 02.34565.1
Fax. +39 02.34565.310
Segreteria Assobiotec
Tel. 02 34565.256/341
assobiotec@federchimica.it